Skip to main content
Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.
Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study.
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma.
Novel influenza A (H1N1) viral infection in pediatric patients with sickle-cell disease.
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Ionizing radiation: an element of danger in every procedure.
Osteosarcoma in children 5 years of age or younger at initial diagnosis.
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.